Immuno-oncology
Uncover how synthetic biology, biomarkers, and GenAI are advancing ADCs - and why CROs are essential to clinical and regulatory success.
The deal, which could be worth over $2bn, looks to bolster Gilead's growing immunology franchise while also granting long-time partner Galapagos a chance at a future royalty stream.
The biotech stopped a Phase III trial combining Merck’s Keytruda with eftilagimod alfa in first-line non-small cell lung cancer due to futility.
Six late-stage data readouts are expected from BioNTech this year, with a potential first US oncology approval by 2027 – but before that, it needs to find a new CEO and chief medical officer.
With J&J’s CAR-T Carvykti also approved for second-line disease, an oncologist told Scrip multiple factors will determine who gets which therapy option.
Qilu’s bifunctional combo of PD-1 and CTLA-4 antibodies hits its marks in a Phase III cervical cancer trial, while Lynk’s JAK1 inhibitor logs similar win in atopic dermatitis.
Moderna will pay $950m upfront under the settlement, which lifts a significant weight off its shoulders, as investors had feared it could be on the hook for $5bn.
Clinical Data Readout: With a median follow-up of 6.5 months, updated findings from a Phase I/II study of DB-1311 (BNT324) in heavily pretreated mCRPC patients worldwide showed a median radiographic progression-free survival of 11.3 months and a median overall survival of 22.5 months.
Sichuan Biokin Pharmaceutical’s iza-bren hit the co-primary endpoints of OS and PFS in a Phase III clinical study in Chinese patients with triple-negative breast cancer in the second and later-line settings.
Vir enters major global deal worth up to $1.7bn for T-cell engager VIR-5500 in an alliance that will also expand partner Astellas's immuno-oncology pipeline ahead of a major expiry.
Pioneering immunologist, Prof. Bruce Levine from UPenn, wears his passion for CAR-T cell therapy on his sleeve as he highlights future uses of the therapy, predictive markers and off-the-shelf CAR-T while speaking about a journey from Kymriah co-inventor to country music co-writer
2026 has already seen some interesting late-stage trial readouts, from Sanofi’s anti-OX40L antibody, amlitelimab, in atopic dermatitis to Vertex’s APRIL/BAFF inhibitor, povetacicept, in IgA nephropathy. Here Scrip surveys of some of the more interesting Phase III clinical trials still to come.
2026 has already seen several major new funding rounds for Chinese biopharma ventures, including a $70m financing for CAR-T specialist Oricell and a $40m Angel round for ADC specialist Tosun.
While Summit/Akeso’s bispecific, ivonescimab, awaits US approval, China’s CStone is moving fast into a broad Phase II study of its trispecific anticancer candidate, with hopes of better safety and efficacy.
Scrip spoke with CMO Dietmar Berger about his views on diversifying Gilead’s virology, oncology and immunology R&D efforts through both in-house research and external innovation.
Enthusiastic predictions from industry leaders for ongoing progress in obesity, oncology, immunology, neuroscience and more were supported by optimism for the potential of AI and other technological advances to enable breakthroughs in processes as well as pipelines.
Given its already large cancer drug pipeline, EVP of oncology R&D Susan Galbraith spoke with Scrip about how AstraZeneca is making precise choices about deals and development programs.
Multiple Chinese biotechs are seeking to raise new funds through IPOs on the Hong Kong and Beijing stock exchanges to support international clinical trials for their first-in-class molecules.
Deal Snapshot: BMS is casting a broad net in oncology as it looks to replace its aging blockbuster Opdivo with a variety of novel cancer therapies.
While a record number of China-originated first-in-class drugs were approved domestically in 2025, only one has so far entered clinical development overseas with its originator as the sole sponsor. But more progress is expected this year.